{
    "clinical_study": {
        "@rank": "137979", 
        "arm_group": {
            "arm_group_label": "Vintafolide", 
            "arm_group_type": "Experimental", 
            "description": "Participants receive vintafolide intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate thrice weekly dosing with vintafolide to find the maximum tolerable\n      dose. The primary study hypothesis is that administration of vintafolide to participants\n      with advanced solid tumors will have acceptable safety and tolerability."
        }, 
        "brief_title": "A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically-confirmed metastatic or locally advanced solid tumor that has failed\n             to respond to standard therapy, progressed despite standard therapy, or for which\n             standard therapy does not exist\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Chemotherapy, radiotherapy, or biological therapy (including monoclonal antibodies)\n             within 4 weeks prior to drug administration (6 weeks for nitrosoureas or mitomycin C)\n             or not recovered from adverse events due to agents administered more than 4 weeks\n             earlier\n\n          -  Primary central nervous system (CNS) tumor\n\n          -  Active CNS metastases and/or carcinomatous meningitis\n\n          -  Known hypersensitivity to the components of the study therapy or its analogs\n\n          -  Recent history of abdominal surgery or peritonitis\n\n          -  Bowel occlusion or sub occlusion\n\n          -  Prior abdominal or pelvis radiation therapy or radiation therapy to > 10% of the bone\n             marrow at any time in the past or prior radiation therapy within the last three years\n             to the breast / sternum, head, or neck\n\n          -  Requires anti-folate therapy\n\n          -  Symptomatic ascites or pleural effusion\n\n          -  Prior stem cell or bone marrow transplant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02049281", 
            "org_study_id": "8109-011", 
            "secondary_id": "142501"
        }, 
        "intervention": {
            "arm_group_label": "Vintafolide", 
            "intervention_name": "Vintafolide", 
            "intervention_type": "Drug", 
            "other_name": "MK-8109"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Folic Acid", 
                "Vinca Alkaloids"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "last_name": "Japan Call Center", 
                "phone": "81-3-6272-1957"
            }, 
            "facility": {
                "address": {
                    "city": "Chiyoda-Ku, Tokyo", 
                    "country": "Japan", 
                    "zip": "102-8667"
                }, 
                "name": "MSD K.K."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants Experiencing Dose-limiting Toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02049281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum Plasma Concentration (Cmax) of Vintafolide", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose"
            }, 
            {
                "measure": "Area Under the Plasma Concentration-time Curve (AUC) for Vintafolide", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose"
            }, 
            {
                "measure": "Plasma Concentration of desacetylvinblastine hydrazide (DAVLBH)", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}